About the journal

Aims and Scope

The BJD strives to publish the highest-quality dermatological research. In so doing, the Journal aims to advance the understanding, management and treatment of skin disease in order to improve the outcomes of patient care. The main focus of the BJD (described in a position statement published in the June 2015 issue) is to publish the highest-quality research encompassing the following:

• Clinical trials that are registered before recruitment starts and report fully according to the CONSORT guidelines.
• Clinical studies that include epidemiology, qualitative research and mixed methods that conform to the STROBE and SRQR reporting guidelines.
• Translational research that describes basic and applied science of potential clinical relevance.
• Systematic reviews following the PRISMA statement, MOOSE guidelines or the ENTREQ statement.

The BJD invites submissions under a broad scope of topics relevant to clinical and experimental research as described in the position statement. The Journal publishes original articles, Reviews, Clinical Guidelines, Research Letters, Perspectives, Case Reports and items of correspondence.

The BJD is an official organ of the British Association of Dermatologists, but attracts contributions from dermatology researchers throughout the world. The BJD editorial board and editorial team include outstanding clinical academics, scientists and clinicians from across the globe. The circulation and readership of the BJD are equally international. The overriding criteria for publication are scientific merit, originality and interest to a multidisciplinary audience.

Mission and values

Founded in 1888, the BJD has evolved into one of the world’s leading general dermatology journals. The BJD brand is underpinned by the provision of trusted information. From this solid foundation, the Journal aims to improve dermatology care globally and serve the needs of patients from diverse backgrounds.

• For authors, the BJD aims to provide timely, high-quality, constructive peer review, which is focused on improving the quality of accepted manuscripts. Article production should be quick and accurate and free of any charges.
• The BJD recognizes the invaluable role of reviewers in safeguarding the integrity of the content, and aims to acknowledge fully their contribution. Our editorial team includes section editors for qualitative research, epidemiology, clinical trials, translational research, case reports and correspondence. Peer reviewers are chosen by the large team of associate editors appointed as subject experts. Statistical review is provided, when needed, by the BJD statistics editor.
• For readers, the BJD aims to deliver the highest-quality clinical and experimental research spanning the continuum of dermatological disciplines and promote understanding and facilitate clinical decision making. Content should reflect the needs of the global populations we serve, with research relevant to the skin health of all communities, including previously understudied groups and vulnerable populations. This includes the health of the LGBTQ community, skin of colour, elderly patients and those with understudied diseases.
• For patients, the BJD publishes Plain Language Summaries. These concise summaries of original research articles are intended to open up BJD content to patients with skin disease worldwide.
• For subscribers, the BJD aims to offer flexible purchasing options – from individual article downloads to multiyear, multisite licenses and transitional agreements – at reasonable prices.
• For sponsors, the BJD aims to offer ethical marketing solutions that yield measurable returns on investment.

Issues :

Volume 188, Issue 1, January 2023
Volume 188, Issue 2, February 2023
Volume 188, Issue 3, March 2023
Volume 188, Issue 4, April 2023
Volume 188, Issue 5, May 2023
Volume 188, Issue 6, June 2023
Volume 189, Issue 1, July 2023
Volume 189, Issue 2, August 2023
Volume 189, Issue 3, September 2023
Volume 189, Issue 4, October 2023
Volume 189, Issue 5, November 2023
Volume 189, Issue 6, December 2023